These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 11935213

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
    Ouchi KF, Yanagisawa M, Sekiguchi F, Tanaka Y.
    Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
    [Abstract] [Full Text] [Related]

  • 3. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
    Fujimoto-Ouchi K, Sekiguchi F, Yamamoto K, Shirane M, Yamashita Y, Mori K.
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):269-76. PubMed ID: 19904537
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, Hindenburg HJ, Lakner V, Hinke A, Bangemann N.
    J Clin Oncol; 2007 Aug 01; 25(22):3246-50. PubMed ID: 17577021
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
    Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y.
    Cancer Chemother Pharmacol; 2007 May 01; 59(6):795-805. PubMed ID: 17031648
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
    Saeki H, Yanoma S, Takemiya S, Sugimasa Y, Akaike M, Yukawa N, Rino Y, Imada T.
    Oncol Rep; 2007 Aug 01; 18(2):433-9. PubMed ID: 17611667
    [Abstract] [Full Text] [Related]

  • 9. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
    Yamamoto D, Iwase S, Kitamura K, Odagiri H, Yamamoto C, Nagumo Y.
    Cancer Chemother Pharmacol; 2008 Mar 01; 61(3):509-14. PubMed ID: 17516068
    [Abstract] [Full Text] [Related]

  • 10. Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
    Kataoka M, Yamaguchi Y, Moriya Y, Sawada N, Yasuno H, Kondoh K, Evans DB, Mori K, Hayashi S.
    Oncol Rep; 2012 Feb 01; 27(2):303-10. PubMed ID: 22076074
    [Abstract] [Full Text] [Related]

  • 11. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D.
    Oncogene; 1999 Apr 01; 18(13):2241-51. PubMed ID: 10327070
    [Abstract] [Full Text] [Related]

  • 12. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, Shiry L, Pegram M, Leyland-Jones B.
    Cancer Res; 2006 Jul 15; 66(14):7245-52. PubMed ID: 16849573
    [Abstract] [Full Text] [Related]

  • 13. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts.
    Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H.
    Clin Cancer Res; 1999 Oct 15; 5(10):2948-53. PubMed ID: 10537364
    [Abstract] [Full Text] [Related]

  • 14. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.
    Cancer Sci; 2012 Feb 15; 103(2):342-9. PubMed ID: 22050138
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of edotecarin in breast carcinoma models.
    Ciomei M, Croci V, Stellari F, Amboldi N, Giavarini R, Pesenti E.
    Cancer Chemother Pharmacol; 2007 Jul 15; 60(2):229-35. PubMed ID: 17089166
    [Abstract] [Full Text] [Related]

  • 16. Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells.
    Bocangel D, Zheng M, Mhashilkar A, Liu Y, Ramesh R, Hunt KK, Chada S.
    Cancer Gene Ther; 2006 Oct 15; 13(10):958-68. PubMed ID: 16783343
    [Abstract] [Full Text] [Related]

  • 17. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ.
    Oncogene; 1998 Oct 29; 17(17):2235-49. PubMed ID: 9811454
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
    Yanagisawa M, Fujimoto-Ouchi K, Yorozu K, Yamashita Y, Mori K.
    Oncol Rep; 2009 Aug 29; 22(2):241-7. PubMed ID: 19578762
    [Abstract] [Full Text] [Related]

  • 19. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
    Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H, Tanaka Y.
    Int J Cancer; 1999 Sep 24; 83(1):127-34. PubMed ID: 10449619
    [Abstract] [Full Text] [Related]

  • 20. Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report.
    Shigekawa T, Takeuchi H, Misumi M, Matsuura K, Sano H, Fujiuchi N, Okubo K, Osaki A, Aogi K, Saeki T.
    Breast Cancer; 2009 Sep 24; 16(1):88-92. PubMed ID: 18478315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.